LON:RLM

Realm Therapeutics (RLM) Share Forecast, Price & News

GBX 11.50

0.00 (0.00%)

(As of 03/26/2019)

Add

Compare

Today's Range: 11.50
▼
11.50
50-Day Range: 11.50
▼
11.50
52-Week Range: 5.80
▼
40

Volume: 169,853 shs
Average Volume: 800,861 shs
Market Capitalization: £13.40 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive RLM News and Ratings via Email

Sign-up to receive the latest news and ratings for Realm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Realm Therapeutics

Realm Therapeutics Plc, a biopharmaceutical company, focuses on developing therapies for the treatment of immune-mediated diseases in adults and children. Its product pipeline includes PRO22, a topical gel, which is conducting initial Phase II clinical studies for the treatment of atopic dermatitis. The company was formerly known as PuriCore plc and changed its name to Realm Therapeutics Plc in December 2016. Realm Therapeutics Plc was founded in 2016 and is headquartered in Malvern, Pennsylvania.

February 28, 2022 | investing.com

Realm Therapeutics PLC ADR (RLM_old)

July 8, 2019 | markets.ft.com

Update on Court Hearing

July 5, 2019 | markets.ft.com

Final Net Cash Amount and Exchange Ratio

June 26, 2019 | markets.ft.com

Update to Court Hearing and Acquisition by Essa

June 26, 2019 | seekingalpha.com

M&A Updates: Cresco Labs/Origin House Transaction Is Not Worth The Risk Anymore

June 16, 2019 | seekingalpha.com

M&A Updates: Realm Therapeutics Deal With Essa Pharma Provides An Interesting Opportunity

June 3, 2019 | seekingalpha.com

Realm Therapeutics: A Cash Grab In Progress

April 10, 2019 | finance.yahoo.com

Realm Therapeutics Announces 2018 Annual Report Available and Form 20-F Filing

March 29, 2019 | seekingalpha.com

Realm Therapeutics completes assets disposal

March 26, 2019 | finance.yahoo.com

Realm Therapeutics Announces Cancellation of AIM Listing

March 15, 2019 | seekingalpha.com

Realm up 10% on shareholder OK on asset disposal

March 15, 2019 | finance.yahoo.com

Realm Therapeutics Announces Result of General Meeting

February 21, 2019 | www.morningstar.co.uk

Bavaria Industries Picks Up 6% Interest In Realm Therapeutics (ALLISS)

See More Headlines

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:RLM
Previous Symbol: LON:PURI
CUSIP: N/A
CIK: N/A
Web: www.realmtx.com
Phone: +1-484-3212700
Fax: N/A
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: £501.92 thousand
Price / Sales: 26.71
Cash Flow: GBX 20.30 per share
Price / Cash Flow: 0.57
Book Value: GBX 20.80 per share
Price / Book: 0.55

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.05
Quick Ratio: 9.96

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 116,562,000
Free Float: N/A
Market Cap: £13.40 million
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

1.08 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Realm Therapeutics.

4.8 Community Rank

Outperform Votes
Realm Therapeutics has received 193 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Realm Therapeutics has received 76 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Realm Therapeutics has received 71.75% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Realm Therapeutics and other stocks. Vote “Outperform” if you believe RLM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RLM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Realm Therapeutics does not currently pay a dividend.
Dividend Growth
Realm Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Realm Therapeutics insiders have not sold or bought any company stock.

0.6 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Realm Therapeutics is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Realm Therapeutics is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Realm Therapeutics has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Realm Therapeutics (LON:RLM) Frequently Asked Questions

Who are Realm Therapeutics' key executives?: Realm Therapeutics' management team includes the following people:
Mr. John Alexander Martin, CEO & Exec. Director (Age 51)
Ms. Marella Thorell, CFO, COO, Company Sec. & Exec. Director (Age 52)
Dr. Christian Peters, Chief Medical Officer (Age 57)
Who are some of Realm Therapeutics' key competitors?: Some companies that are related to Realm Therapeutics include Acasti Pharma (ACST), Asterias Biotherapeutics (AST), Emerald Health Therapeutics (EMH), Synairgen (SNG), Ceapro (CZO), ProMIS Neurosciences (PMN), Small Pharma (DMT), Sirona Biochem (SBM), SkinBioTherapeutics (SBTX), Brooklyn ImmunoTherapeutics (BTX), Brooklyn ImmunoTherapeutics (BTX), OKYO Pharma (OKYO), Antibe Therapeutics (ATE), Neptune Wellness Solutions (NEPT) and Destiny Pharma (DEST).
View all of RLM's competitors.
What other stocks do shareholders of Realm Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Realm Therapeutics investors own include Allena Pharmaceuticals (ALNA), AcelRx Pharmaceuticals (ACRX), Ampliphi Biosciences (APHB), Viking Therapeutics (VKTX), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), Aldeyra Therapeutics (ALDX), (ALT), Ampio Pharmaceuticals (AMPE) and Apellis Pharmaceuticals (APLS).
What is Realm Therapeutics' stock symbol?: Realm Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "RLM."
How do I buy shares of Realm Therapeutics?: Shares of RLM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Realm Therapeutics' stock price today?: One share of RLM stock can currently be purchased for approximately GBX 11.50.
How much money does Realm Therapeutics make?: Realm Therapeutics has a market capitalization of £13.40 million and generates £501.92 thousand in revenue each year.
What is Realm Therapeutics' official website?: The official website for Realm Therapeutics is www.realmtx.com.
How can I contact Realm Therapeutics?: Realm Therapeutics' mailing address is 508 Lapp Rd, MALVERN, PA 19355-1214, United States. The company can be reached via phone at +1-484-3212700.

This page was last updated on 5/28/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.